In a world first, a bespoke gene-editing therapy benefitted one child. Now reseachers plan to launch a clinical trial of the ...

Explore how oligonucleotides are reshaping therapeutics, diagnostics and CRISPR with rapid, scalable and personalized ...

A live webcast of the presentation will be accessible via Caribou’s website on the Events page. The archived webcast will be available on the Caribou website for 30 days after the event. About ...

Health Secretary Robert F. Kennedy Jr. called the treatment 'a powerful glimpse into the future of personalized medicine' ...

Intellia Therapeutics also has fans on Wall Street. The company's current average price target of $32.3 (according to Yahoo!

Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of ...

We are now in the second great wave of the genetic revolution, not defined by reading the human code of life, but by rewriting it.

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has ...

The US FDA is set to introduce a faster approval process for personalized gene editing therapies, aiming to accelerate investment and development of treatments for rare diseases, highlighted by the ...

Strong Trikafta/Kaftrio demand, along with contributions from Alyftrek, Casgevy and Journavx, may have helped VRTX outperform ...

In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...

Ozempic, MRI machines and flat screen televisions all emerged out of fundamental research decades earlier — the very types of ...